چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | نسترن هاشم زاده |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | کمیته تحقیقات دانشجویی |
| کد مقاله | 69016 |
| عنوان فارسی مقاله | توام درمانی داروهای متفورمین و ارلوتینیب با استفاده از نانوذرات مغناطیسی پوشش دهی شده با سیلیکا در سلولهای MCF-7 دو بعدی و سه بعدی |
| عنوان لاتین مقاله | COMBINATION THERAPY OF METFORMIN AND ERLOTINIB USING MESOPOROUS SILICA MAGNETIC NANOPARTICLES IN 2D AND 3D CULTURED MCF-7 CELLS |
| نوع ارائه | سخنرانی |
| عنوان کنگره / همایش | Asian Federation for Medicinal Chemistry (AFMC) 12th International Symposium |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | Turkey |
| شهر محل برگزاری کنگره/ همایش | Istanbul |
| سال انتشار/ ارائه شمسی | 1398 |
| سال انتشار/ارائه میلادی | 2019 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1398/06/17 الی 1398/06/20 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | https://aimecs2019.org/e-abstract-book |
| آدرس علمی (Affiliation) نویسنده متقاضی | 1) Student Research Committee, Faculty Of Pharmacy, Tabriz University Of Medical Sciences, Tabriz, Iran 2) Department Of Pharmaceutics, Faculty Of Pharmacy, Tabriz University Of Medical Sciences, Tabriz, Iran 3) Research Center For Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University Of Medical Sciences, Tabriz, Iran |
| نویسنده | نفر چندم مقاله |
|---|---|
| میترا دولت خواه | دوم |
| ژاله برار | سوم |
| خسرو ادیب کیا | چهارم |
| ایوب آقانژاد | پنجم |
| نسترن هاشم زاده | اول |
| یداله امیدی | ششم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Over the past few decades, there has been comprehensive progress in terms of improving a more effective chemotherapeutic regimen for targeted Breast cancer therapy. To overcome cancer resistance to monotherapies, drug combinations of two or more compounds with different mechanisms of action are developed. We explored 2 agents with promising preclinical data in in-vitro assays. Firstly, Erlotinib used as a tyrosine kinase inhibitor. This agent is a promising class of Anti-angiogenic agents which has attracted a lot of attention in combinational therapy. The second drug was metformin. It is generally a safe and effective medication in type 2 diabetes. Several studies represent its efficacy in cancer study. The thermal decomposition process was used for synthesizing the magnetic core. To obtain a mesoporous silica shell, NaOH, acetone solution of APTES, NH4NO3, and NaBH4 used. The reaction mixture was then stirred at room temperature overnight. The success of this synthesis was confirmed by DLS, TEM, SEM, FT-IR and VSM methods. In the next step, The Encapsulation efficiency (EE %) and Loading Capacity (LC %) of each drug was calculated. the pH-responsive release profile of Metformin and Erlotinib from MSMNPs in PBS (pH 5.4, 6.4 or 7.4) was plotted. The experiments were repeated three times. The results indicated that the release of drug molecules and the release rate was greatly dependent on the pH value. For Cytotoxicity assay firstly we determined ic50 of both-agent including metformin and erlotinib in 2D and 3D MCF-7 cell lines. To define synergistic combinations of these drugs we use Combenefit and CompuSyn software. All statistical analysis was performed using SPSS 17.0.0 software. Finally, we choose the combinations which include less molar concentration of Erlotinib that may have less adverse effects. In the current study, we highlighted metformin’s potential to improve clinical outcomes of breast cancer therapy in our assays and also demonstrated its synergistic effect in |
| کلمات کلیدی | Breast cancer, Erlotinib, Metformin, combinational therapy. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| AIMCS2019Abstract_book.pdf | 1398/06/30 | 12625137 | دانلود |
| document (12).pdf | 1398/06/30 | 4232787 | دانلود |
| 2 (1).docx | 1398/07/02 | 15827 | دانلود |
| 1.docx | 1398/07/02 | 14373 | دانلود |
